体质指数与心房的患者进行皮肤冠状动脉干预的临床事件之间的关系
Tatsuro Yamazaki1, Hideki Kitahara1, Daichi Yamashita1
1Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
PloS one
|September 19, 2024
概括
通过皮肤冠状动脉干预 (PCI) 接受心房动 (AF) 患者的下体质指数 (BMI) 与不良心血管和出血事件的风险更高有关. 这一发现凸显了BMI作为患者结果的关键预测指标.
科学领域:
- 心脏病学 心脏病学
- 临床研究 临床研究
- 肥胖医学 肥胖医学
背景情况:
- 身体质量指数 (BMI) 对心房 (AF) 患者进行皮肤冠状动脉干预 (PCI) 的临床结果的影响,同时对口服抗凝剂 (OAC) 和抗血小板治疗的影响仍然不清楚.
- 这项研究调查了BMI与这种特定患者群体的不良事件之间的关联.
研究的目的:
- 评估BMI和临床事件之间的关系,特别是冠状动脉疾病 (CAD) 进行PCI的AF患者的净不良临床事件 (NACE) 和重大出血.
主要方法:
- 这是一项多中心的观察性队列研究,涉及来自日本15所机构的720名患者.
- 根据BMI,患者被分为两组:第一组 (BMI <21.3 kg/m2) 和第二组 (BMI ≥21.3 kg/m2).
- 主要终点是NACE,主要不良心血管事件 (MACE) 和PCI后一年内主要出血事件的组合.
主要成果:
- 与第二组相比,较低BMI (1组) 的患者表现出NACE (21.1%对11.9%) 和MACE (17.2%对8.9%) 的比率明显更高.
- 两组之间没有观察到主要出血事件的显著差异 (5.6%对4.3%).
- 在多变量分析中,较低的BMI (<21.3 kg/m2) 被确定为增加NACE和MACE的独立预测因子,但不是主要出血.
结论:
- 在为CAD接受PCI并需要OAC的AF患者中,BMI是预测重大不良临床事件的有价值指标.
- 较低的BMI (<21.3 kg/m2) 与不良心血管事件的风险增加有关,独立于出血风险.
更多相关视频
相关概念视频
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...